Jaguar Health (JAGX) Gains from Sales and Divestitures (2016 - 2026)

Jaguar Health (JAGX) reported Gains from Sales and Divestitures of $51.0 for Q1 2026, down 98.44% quarter-over-quarter from $3260.0 in Q4 2025.

Jaguar Health (JAGX) Gains from Sales and Divestitures (2016 - 2026) Analysis & Trends

Jaguar Health (JAGX) has 4 years of Gains from Sales and Divestitures data on file, last reported at $51.0 in Q1 2026.

Gains from Sales and Divestitures for Q1 2026 came in at $51.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $51.0 (changed N/A YoY), and the FY2025 annual result was $3260.0, changed N/A from the prior year.
Gains from Sales and Divestitures fell to $51.0 in Q1 2026 per JAGX's latest filing, from $3260.0 in the prior quarter.
Over five years, Gains from Sales and Divestitures peaked at $3260.0 in Q4 2025 and troughed at $4.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn
9	Abivax	94.26 Bn	94.26 Bn	-
10	Jaguar Health	1.44 Mn	-10.19 Mn	19.11 Mn

Download Data